PureTech, Seaport Advance GlyphAllo in Depression Therapy
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
DENVER, USA – March 18, 2026 TriSalus Life Sciences has announced new preclinical findings demonstrating that its Pressure-Enabled Drug...
Tacares de Grecia, Alajuela, Costa Rica – December 9, 2025 – Forj Medical, the newly formed CDMO created by...
September 18, 2025 — Cambridge, Massachusetts Biogen has announced the acquisition of Alcyone Therapeutics, a Massachusetts-based biotech company specializing...
